Effect of intermittent preventive treatment for malaria during infancy on serological responses to measles and other vaccines used in the Expanded Programme on Immunization: Results from five randomised controlled trials

The Lancet

Volumn 380, Issue 9846, 2012, Pages 1001-1010

  Crawley, Jane ^a,b   Sismanidis, Charalambos ^c   Goodman, Tracey ^d   Milligan, Paul ^d,e  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Global Malaria Programme   (United Kingdom)

^c STOP TB Department ^*  (Switzerland)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ARTESUNATE; CHLORPROGUANIL PLUS DAPSONE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; MEASLES VACCINE; MEFLOQUINE; PLACEBO; PYRIMETHAMINE PLUS SULFADOXINE;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOSE RESPONSE; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GHANA; HEALTH PROMOTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFANT; KENYA; MAJOR CLINICAL STUDY; MALARIA; MALARIA CONTROL; MEASLES; MOZAMBIQUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; TANZANIA;

EID: 84866183303     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60775-2     Document Type: Article

References (42)

1. WHO. World malaria report. Geneva: World Health Organization, 2
2. Aponte JJ, Schellenberg D, Egan A, et al. Effi cacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 2009; 374: 1533-42.
3. WHO. Immunization surveillance, assessment and monitoring. Data, statistics and graphics. http://www.who.int/immunization-monitoring/data/en/ (accessed June 25, 2012).
4. Chandramohan D, Owusu-Agyei S, Carneiro I, et al. Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ 2005; 331: 727-33.
5. Gosling RD, Gesase S, Mosha JF, et al. Protective effi cacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1521-32.
6. Macete E, Aide P, Aponte JJ, et al. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J Infect Dis 2006; 194: 276-85.
7. Odhiambo FO, Hamel MJ, Williamson J, et al. Intermittent preventive treatment in infants for the prevention of malaria in rural Western Kenya: a randomized, double-blind placebo-controlled trial. PLoS One 2010; 5: e10016.
8. Farrington, CP, Manning, G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk diff erence or non-unity relative risk. Stat Med 1990; 9: 1447-54.
9. WHO. Immunization, vaccines and biologicals. SAGE meeting of Oct 27-29, 2009. http://www.who.int/immunization/sage/previous-october2009/en/index.html (accessed June 25, 2012).
10. Benn C, Aaby P, Nielsen J, Binka A, Ross D. Does vitamin A supplementation interact with routine vaccinations? An analysis of the Ghana Vitamin A supplementation trial. Am J Clin Nutr 2009; 90: 629-39.
11. Savy M, Edmond K, Fine P, et al. Landscape analysis of interactions between nutrition and vaccine responses in children. J Nutr 2009; 139: S2154-218.
12. Benn C, Fisker A, Napirna B, et al. Vitamin A supplementation and BCG vaccination at birth in low birthweight neonates: two by two factorial randomised controlled trial. BMJ 2010; 340: c1101.
13. WHO. Measles vaccines: WHO position paper. Wkly Epidemiol Rec 2009; 84: 349-60.
14. WHO. Weekly epidemiological record. http://www.who.int/wer/2009/wer8435. pdf (accessed June 25, 2012).
15. Albrecht P, Herrmann K, Burns GR. Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods 1981; 3: 251-60.
16. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162: 1036-42.
17. Schellenberg D, Menendez C, Kahigwa E, et al. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet 2001; 357: 1471-77.
18. Schellenberg D, Menendez C, Aponte JJ, et al. Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet 2005; 365: 1481-83.
19. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17: 1055-65.
20. Cohen BJ, Doblas D, Andrews N. Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specifi c IgG ELISA for assessing immunogenicity of measles vaccination. Vaccine 2008; 26: 6392-97.
21. Rosen JB, Breman JG. Malaria intermittent preventive treatment in infants, chemoprophylaxis, and childhood vaccinations. Lancet 2004; 363: 1386-88.
22. Cunningham AJ, Riley EM. Suppression of vaccine responses by malaria: insignifi cant or overlooked? Expert Rev Vaccines 2010; 9: 409-29.
23. Klein SL, Jedlincka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 2010; 105: 338-49.
24. Alassane Dicko A, Konare M, Traore D, et al. The implementation of malaria intermittent preventive treatment with sulphadoxinepyrimethamine in infants reduced all-cause mortality in the district of Kolokani, Mali: results from a cluster randomized control trial. Malar J 2012; 11: 73.
25. Schellenberg J, Maokola W, Shirima, et al. Cluster-randomised study of intermittent preventive treatment for malaria in infants (IPTi) in southern Tanzania: evaluation of impact on survival. Malaria J 2011; 10: 387.
26. Mason RA, Tauraso NM, Spertzel RO, Ginn RK. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 1973; 25: 539-44.
27. WHO. Guidelines for the treatment of malaria. Geneva: World Health Organization, 2006.
28. Barnes KI, Little F, Smith PJ, Evans A, Watkins WM, White NJ. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther 2006; 80: 582-96.
29. Bell DJ, Nyirongo SK, Mukaka M, Molyneux ME, Winstanley PA, Ward SA. Population pharmacokinetics of sulfadoxine and pyrimethamine in Malawian children with malaria. Clin Pharmacol Ther 2011; 89: 268-75.
30. Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T. Intercontinental spread of pyrimethamine-resistant malaria. Science 2004; 305: 1124.
31. Moss WJ, Clements CJ, Halsey NA. Immunization of children at risk of infection with human immunodefi ciency virus. Bull World Health Organ 2003; 81: 61-70.
32. Prymula R, Siegrist C-A, Chlibek R, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet 2009; 374: 1339-50.
33. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47: 401-09.
34. Gallagher MR, Welliver R, Yamanaka T, Eisenberg B, Sun M, Ogra PL. Cell-mediated immune responsiveness to measles. Its occurrence as a result of naturally acquired or vaccine-induced infection and in infants of immune mothers. Am J Dis Child 1981; 135: 48-51.
35. Reich A, Erlwein O, Niewiesk S, ter Meulen V, Liebert UG. CD4+ T cells control measles virus infection of the central nervous system. Immunology 1992; 76: 185-91.
36. Carneiro I, Roca-Feltrer A, Griffi n JT, et al. Age-patterns of malaria vary with severity, transmission intensity and seasonality in sub-Saharan Africa: a systematic review and pooled analysis. PLoS One 2010; 5: e8988.
37. Wilson AL. A systematic review and meta-analysis of the effi cacy and safety of intermittent preventive treatment of malaria in children (IPTc). PLoS One 2011; 6: e16976.
38. WHO. WHO global malaria programme. http://www.who.int/malaria/ publications/atoz/smc-policy-recommendation-en-032012. pdf (accessed June 25, 2012).
39. Hutton G, Schellenberg D, Tediosi F, et al. Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the United Republic of Tanzania. Bull World Health Organ 2009; 87: 123-29.
40. Pool R, Mushi A, Schellenberg JA, et al. The acceptability of intermittent preventive treatment of malaria in infants (IPTi) delivered through the expanded programme of immunization in southern Tanzania. Malar J 2008; 7: 213.
41. WHO. Co-administration of intermittent preventive treatment in infants (IPTi) for malaria at time of immunization. Wkly Epidemiol Rec 2009; 84: 529-30.
42. WHO. Malaria. WHO policy recommendation on Intermittent preventive treatment during infancy with sulfadoxine-pyrimethamine (SP-IPTi) for Plasmodium falciparum malaria control in Africa. http://www.who.int/malaria/news/policy- recommendation-IPTi-032010/en/(accessed June 25, 2012).